Scalable Clinical Evidence: PSG-Grade Data for Global Clinical Trials
Traditional clinical trials involving sleep endpoints are often hindered by the high cost and geographical limitations of brick-and-mortar sleep labs. DormoVision X™ removes these barriers, offering a decentralized, Type II polysomnography solution that delivers in-lab precision with the ease of a home-based wearable. By capturing 38 channels of high-fidelity physiological data—including full EEG for sleep staging—DormoVision X™ enables researchers to collect objective, ecologically valid sleep biomarkers across diverse populations without sacrificing the rigor of gold-standard PSG.
Key Benefits
Decentralized Trials: Test From Anywhere. The wireless architecture and cloud-integrated platform allow researchers to deploy PSG-grade studies across multiple sites or directly in subjects’ homes simultaneously. Real-time monitoring capabilities enable remote investigators to verify signal quality and subject compliance as it happens, drastically increasing study throughput and reducing the logistical burden of traditional site-bound trials.
Validated Longitudinal Data Capture multiple nights of PSG-grade data to mitigate the “first-night effect” and account for night-to-night variability, significantly strengthening statistical power and reducing the number of subjects required to reach significance.
Objective Sleep Biomarkers Transition from subjective sleep diaries to objective neuro-sleep metrics. High-resolution EEG allows for the precise measurement of REM architecture, Slow Wave Sleep (SWS), and micro-arousals—essential for CNS, psychiatry, and respiratory trials.
High Subject Retention: A lightweight, cannula-free design (rated 4.2/5 for comfort) improves subject compliance and reduces study drop-out rates, particularly in pediatric (ages 6+) and sensitive populations.
Features
- One Platform, Full PSG Capability At Home or In-Lab.
- Wireless, Remote, And FDA-Cleared.
- 38 Total Channels For Comprehensive Sleep Data.
- Faster Diagnoses with Greater Clinical Confidence.
- Expand Capacity, Reduce Costs, No Added Overhead.
- Patient-Friendly Solution for Diagnosing Complex Sleep Disorders in Children
Validated via NCT06224972 (N=47)
-
Nox A1 Comparison: Virtually identical mean AHI values recorded head-to-head.
-
Severity Match: Near-perfect alignment in distinguishing mild, moderate, and severe OSA cases.
-
Signal Reliability: Strong correlations across all secondary sleep parameters with minimal variance.